Alexandra C. Walls

This study identifies potent MPXV antigens for mRNA vaccine development by testing neutralizing antibodies against various surface proteins in mice.

The paper introduces CoV-UniBind, a unified database of SARS-CoV-2 antibody-antigen interactions, and benchmarks models for antibody design and vaccine development.

This paper develops an mRNA-launched nanoparticle vaccine that combines protein nanoparticle and mRNA vaccine advantages, showing enhanced antibody and T cell responses in mice.

This paper designs multivalent RBD nanoparticle vaccines that overcome immune imprinting and provide broad protection against SARS-CoV-2 variants and sarbecoviruses.

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

The paper introduces a thermodynamically coupled biosensor to rapidly detect neutralizing antibodies against SARS-CoV-2 strains in serum samples.

The paper designs and characterizes trivalent miniprotein binders that neutralize SARS-CoV-2 variants with low pM IC50 values and provide prophylactic and therapeutic protection in mice.

The paper designs picomolar SARS-CoV-2 miniprotein inhibitors using computational methods and experimental validation, showing high potency and structural similarity to computational models.